Tumor-infiltrating lymphocytes for the treatment of metastatic cancer

Over the past few years melanoma incidence has been rising steadily, resulting in an increase in melanoma related mortality. Until recently, therapeutic options for metastatic melanoma were scarce. Chemotherapy and, in some countries, IL-2 were the only registered treatment modalities. In the last five years, treatment with immunotherapy (anti CTLA-4, anti PD-1, or the combination of these antibodies) has shown very promising results and was able to improve survival in patients with metastatic melanoma.

Source: Molecular Oncology - October 29, 2015 Category: Cancer & Oncology Authors: M.H. Geukes Foppen, M. Donia, I.M. Svane, J.B.A.G. Haanen Source Type: research